Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03), Briefing.com reports. During the same period in the previous year, the company posted ($0.72) earnings per share.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded up $0.15 during mid-day trading on Thursday, hitting $29.70. The company had a trading volume of 625,006 shares, compared to its average volume of 1,071,400. Denali Therapeutics has a one year low of $14.56 and a one year high of $32.13. The firm has a fifty day moving average price of $27.57 and a 200 day moving average price of $23.36. The company has a market capitalization of $4.25 billion, a PE ratio of -10.37 and a beta of 1.40.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DNLI shares. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Wedbush decreased their price objective on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Citigroup upped their price target on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.